In this study, although it has been proven that TUSC7 acts as a tumor suppressor in gliomas and has the potential to be a biomarker, in vivo and in vitro experiments are still needed for further validation, thus providing bases for clinical transformation. This evidence concerns the gene TUSC7 and central nervous system cancer.